We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+15.28%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.5B
AUM Growth
+$440M
Cap. Flow
+$58.8M
Cap. Flow %
3.91%
Top 10 Hldgs %
53.02%
Holding
49
New
11
Increased
14
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
LH icon
Labcorp
LH
+$51.4M
2
MDCO
Medicines Co
MDCO
+$32.7M
3
BSX icon
Boston Scientific
BSX
+$32M
4
KND
Kindred Healthcare
KND
+$29.7M
5
GSK icon
GSK
GSK
+$24.6M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$44.9M
2
VTRS icon
Viatris
VTRS
+$34.9M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$32.4M
4
VOLC
VOLCANO CORPORATION COM STK
VOLC
+$30M
5
DGX icon
Quest Diagnostics
DGX
+$19.1M

Sector Composition

Rank Sector Weight
1 Healthcare 70.89%
2 Miscellaneous 27.21%
3 Consumer Discretionary 1.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$799B
$206M 13.67%
+1,000,000
New +$201M
TEVA icon
2
Teva Pharmaceutical Industries Limited
TEVA
$45.8B
$101M 6.69%
1,750,000
– –
MASI
3
DELISTED
Masimo
MASI
$75.1M 4.99%
2,850,000
+150,000
+6% +$3.7M
GSK icon
4
GSK
GSK
$100B
$74.8M 4.97%
1,400,000
+440,000
+46% +$24.6M
GHDX
5
DELISTED
Genomic Health, Inc.
GHDX
$68.7M 4.57%
2,150,000
+150,000
+8% +$4.88M
CNMD icon
6
CONMED
CNMD
$1.41B
$62.3M 4.14%
1,385,000
– –
ESRX
7
DELISTED
Express Scripts Holding Company
ESRX
$59.3M 3.94%
700,000
– –
LH icon
8
Labcorp
LH
$26.3B
$54M 3.59%
+582,000
New +$51.4M
ARIA
9
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$51.5M 3.43%
7,500,000
+1,500,000
+25% +$9.38M
VOLC
10
DELISTED
VOLCANO CORPORATION COM STK
VOLC
$45.6M 3.03%
2,550,000
-2,500,000
-50% -$30M
GSK icon
11
CALL
GSK
GSK
$100B
$42.7M 2.84%
800,000
– –
AMAG
12
DELISTED
AMAG Pharmaceuticals
AMAG
$42.6M 2.83%
1,000,000
+250,000
+33% +$9.03M
KERX
13
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$42.5M 2.82%
3,000,000
-500,000
-14% -$7.75M
UAM
14
DELISTED
Universal American Corp
UAM
$42.4M 2.82%
4,568,898
+390,639
+9% +$3.4M
VTRS icon
15
Viatris
VTRS
$19.1B
$42.3M 2.81%
750,000
-650,000
-46% -$34.9M
BRKR icon
16
Bruker
BRKR
$8.49B
$39.2M 2.61%
2,000,000
+1,000,000
+100% +$19.2M
OFIX icon
17
Orthofix Medical
OFIX
$370M
$37.6M 2.5%
1,250,000
+39,836
+3% +$1.17M
MDCO
18
DELISTED
Medicines Co
MDCO
$36.5M 2.43%
+1,320,000
New +$32.7M
BSX icon
19
Boston Scientific
BSX
$63.6B
$33.1M 2.2%
+2,500,000
New +$32M
SQNM
20
DELISTED
SEQUENOM INC NEW
SQNM
$32.4M 2.15%
8,750,000
+750,000
+9% +$2.43M
PFNX
21
CALL
DELISTED
Pfenex Inc.
PFNX
$31.1M 2.07%
+1,000,000
New +$7.57M
TEVA icon
22
CALL
Teva Pharmaceutical Industries Limited
TEVA
$45.8B
$28.8M 1.91%
500,000
– –
WW
23
DELISTED
WW International
WW
$28.5M 1.89%
1,146,741
+146,741
+15% +$3.94M
KND
24
DELISTED
Kindred Healthcare
KND
$27.3M 1.81%
+1,500,000
New +$29.7M
PTCT icon
25
PTC Therapeutics
PTCT
$5.48B
$27.2M 1.81%
525,000
+366,851
+232% +$16.1M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, Camber Capital Management held 49 positions worth $1.5B, up 41% from $1.06B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Camber Capital Management deployed $58.8M of net new capital in Q4 2014, opening 11 new positions and adding to 14 existing holdings. Its largest new stake was Labcorp: 582,000 shares worth $54M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 81% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

On the sell side, the largest reduction was Viatris, an estimated $34.9M trimmed.

  • Camber Capital Management's largest Q4 2014 buy was Labcorp: 582,000 shares worth $54M.
  • Camber Capital Management added most to GSK in Q4 2014, an estimated $24.6M increase.
  • Camber Capital Management's biggest Q4 2014 reduction was Viatris, cutting an estimated $34.9M.
  • Camber Capital Management fully exited Vertex Pharmaceuticals in Q4 2014, selling an estimated $44.9M.
  • Camber Capital Management's ten largest holdings make up 53% of its $1.5B portfolio in Q4 2014.
  • Camber Capital Management opened 11 new positions and closed 6 in Q4 2014.
  • Camber Capital Management's portfolio value rose 41% quarter-over-quarter to $1.5B.

Based on Camber Capital Management's 13F filing for Q4 2014, filed 13 Feb 2015.